Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.

@article{Goebel2006ShorttermAA,
  title={Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.},
  author={Frank Dr Goebel and Alexy Yakovlev and Anton Louis Pozniak and Elena Nikolaevna Vinogradova and Griet Boogaerts and Richard M. W. Hoetelmans and Marie-Pierre P de B{\'e}thune and Monika Peeters and Brian J Woodfall},
  journal={AIDS},
  year={2006},
  volume={20 13},
  pages={
          1721-6
        }
}
OBJECTIVE To evaluate antiviral activity, pharmacokinetics, tolerability and safety of TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), when given as a 25, 50, 100 or 150 mg once-daily dose for 7 days to antiretroviral-naive HIV-infected subjects. DESIGN Randomized, double-blind, placebo-controlled, phase IIa clinical trial. METHODS Participants were 47 antiretroviral naive HIV-infected subjects. Primary outcome was the change in plasma HIV-1 RNA viral load from baseline to… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 46 CITATIONS

Effects of rilpivirine on human adipocyte differentiation , gene 2 expression and release of adipokines and cytokines 3 4 5 6 7

Julieta Díaz-Delfína, Pere Domingob, +4 authors Francesc Villarroyaa
  • 2012
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED